CD47 Inhibitor

CL121 is a Glutaminyl Cyclase inhibitor with an IC₅₀ of 0.07 μM against human sQC and an IC₅₀ of 0.54 μM against human gQC. CL121 reduces the level of pyroglutamate (pE)-modified CD47 on the surface of cancer cells. CL121 exhibits anti-tumor activity against triple-negative breast cancer.

SHR-1603 is a humanized anti-CD47 IgG4 antibody. SHR-1603 blocks the interaction of CD47 with SIRPα and enhances phagocytosis. SHR-1603 includes active Fc domains to mediate CDC/ADCC functions. SHR-1603 can be used for the research of cancer^[1][2].

IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research.

AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma.